CKPT Checkpoint Therapeutics Inc
Price (delayed)
$4.04
Market cap
$338.41M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.42
Enterprise value
$331.8M
Checkpoint Therapeutics, Inc. ('Checkpoint') is a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. Checkpoint is
Highlights
CKPT's EPS has surged by 55% year-on-year and by 23% since the previous quarter
The company's quick ratio rose by 27% QoQ and by 22% YoY
CKPT's gross profit has plunged by 60% YoY and by 13% from the previous quarter
Checkpoint Therapeutics's revenue has shrunk by 60% YoY and by 13% QoQ
Key stats
What are the main financial stats of CKPT
Market
Valuations
Earnings
Shares outstanding
83.76M
Market cap
$338.41M
Enterprise value
$331.8M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
3,909.38
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8,092.72
Revenue
$41,000
Gross profit
$41,000
Operating income
-$56.17M
Net income
-$56.24M
EBIT
-$56.24M
EBITDA
-$56.24M
Free cash flow
-$31.1M
Per share
Balance sheet
Liquidity
EPS
-$1.42
EPS diluted
-$1.42
Free cash flow per share
-$0.78
Book value per share
-$0.26
Revenue per share
$0
TBVPS
$0.19
Total assets
$7.47M
Total liabilities
$20.1M
Debt
$0
Equity
-$12.63M
Working capital
-$12.63M
Debt to equity
0
Current ratio
0.37
Quick ratio
0.33
Net debt/EBITDA
0.12
Margins
Efficiency
Dividend
EBITDA margin
-137,170.7%
Gross margin
100%
Net margin
-137,170.7%
Operating margin
-137,009.8%
Return on assets
-742.6%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
N/A
Return on sales
-137,170.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CKPT stock price
How has the Checkpoint Therapeutics stock price performed over time
Intraday
0%
1 week
-0.49%
1 month
41.26%
1 year
110.42%
YTD
26.25%
QTD
0%
Financial performance
How have Checkpoint Therapeutics's revenue and profit performed over time
Revenue
$41,000
Gross profit
$41,000
Operating income
-$56.17M
Net income
-$56.24M
Gross margin
100%
Net margin
-137,170.7%
CKPT's net margin has dropped by 173% year-on-year and by 39% since the previous quarter
The company's operating margin has shrunk by 171% YoY and by 72% QoQ
CKPT's gross profit has plunged by 60% YoY and by 13% from the previous quarter
Checkpoint Therapeutics's revenue has shrunk by 60% YoY and by 13% QoQ
Growth
What is Checkpoint Therapeutics's growth rate over time
Valuation
What is Checkpoint Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
3,909.38
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8,092.72
CKPT's EPS has surged by 55% year-on-year and by 23% since the previous quarter
The equity has grown by 3.2% YoY
CKPT's price to sales (P/S) is 119% higher than its last 4 quarters average of 1788.2
Checkpoint Therapeutics's revenue has shrunk by 60% YoY and by 13% QoQ
Efficiency
How efficient is Checkpoint Therapeutics business performance
CKPT's return on sales has dropped by 173% year-on-year and by 39% since the previous quarter
The return on assets is up by 22% year-on-year but it has declined by 13% since the previous quarter
Dividends
What is CKPT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CKPT.
Financial health
How did Checkpoint Therapeutics financials performed over time
The total assets is 63% less than the total liabilities
The total assets has grown by 44% from the previous quarter and by 39% YoY
The company's current ratio rose by 28% QoQ and by 28% YoY
CKPT's debt is 100% greater than its equity
The equity has grown by 3.2% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.